22
Mar
2006
High Country Venture Colorado Fund I announced completion of a seed investment in TheraTogs, Inc., a provider of orthotic garments that assist children and adults with mobility or postural alignment problems, functional disabilities and neuromotor impairments due to cerebral palsy, ataxia and stroke. Details of the financing have not been disclosed. The fund has also [...]
15
Mar
2006
The Colorado BioScience Association, Tomlinson Associates, and friends have been busy helping to lobby for a series of new bills that would positively impact the Colorado bio-landscape. I have previously mentioned one of the bills here, and identify all of the legislation below: HB06-1308 House Sponsor – Massey, Borodkin, Jahn, Penry, WhiteSenate Sponsor – John [...]
10
Mar
2006
Allos Therapeutics, Inc. announced today the appointment of Paul L. Berns as the Company’s President, Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Berns brings close to 15 years of pharmaceutical industry experience to Allos. While leading Bone Care International, Inc. from June 2002 until its acquisition by Genzyme, [...]
10
Mar
2006
The previous week or two the traffic on this blog has doubled and tripled. I wish I could say it is because of the stimulating and timely content that gets posted here. Rather, this dramatic increase has come via people all over the country and world doing web searches on Necrotizing Fasciitis and often landing [...]
09
Mar
2006
More Good News for Myogen
Posted in CO Public: Myogen
The FDA has granted Fast Track status for Myogen’s ambrisentan, currently in Phase III clinical trials. This designation is aimed to expedite the review process. The FDA designated ambrisentan as a Fast Track product for the following reasons: 1. Ambrisentan is intended to treat PAH, a life-threatening, progressive, and incurable disease of the pulmonary vasculature.2. [...]
07
Mar
2006
Myogen signed off on a two-tiered relationship with GlaxoSmithKline (GSK) whereby first, commercialization rights to ambrisentan have been licensed to GSK for all territories ex-US and secondly, Myogen will now be responsible for marketing and distributing GSK’s Flolan (for the treatment of primary pulmonary hypertension) in the US. Myogen President and CEO J. William Freytag [...]
06
Mar
2006
The Infectious Disease Society of America (IDSA) recently released their ‘hit list’ of dangerous superbugs. IDSA’s Bad Bugs, No Drugs report showed a steady 20-year decline in the number of new FDA-approved antimicrobials and total withdrawal from the field by many major pharmaceutical companies. Happily I can report that I know of more than one [...]
03
Mar
2006
ARCA Discovery, Inc., a company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, today announced the completion of a $15 million venture capital financing. The financing was led by Atlas Venture. Boulder Ventures, which provided the original seed financing for ARCA, and Pequot Capital Management also participated in the financing. This round of [...]
01
Mar
2006
Colorado Bill HB06-1308
Posted in My Rants
HB06-1308 permits the Colorado economic development commission to purchase the right to make a deduction for a net operating loss from a bioscience company (future tax benefit). The Bill requires the general assembly to appropriate at least $2.5 million for the each of the next 5 state fiscal years to purchase these future tax benefits. [...]
Life Science Deal Flow PARTNERS
-
